for educational and safety purposes
Every compound in the sci-wiki that affects insulin secretion; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
3 sourced · 0 reference
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily pill. Eli Lilly is developing it (code LY3502970) for type 2 diabetes and obesity; it is not approved and remains in late-stage trials as of 2026. What makes it notable is the chemistry, not a new mechanism. Because it is a small molecule rather than a peptide, it is absorbed from the gut on its own, without an absorption enhancer and without the food and water restrictions that oral semaglutide requires. In phase 3 trials it lowered blood sugar and body weight meaningfully, though by less than the strongest injectables, with the gastrointestinal side effects typical of the class.
Glimepiride and metformin is a fixed-dose combination medication used to treat type 2 diabetes mellitus, pairing two oral glucose-lowering drugs with complementary actions. Metformin is a biguanide that lowers blood sugar chiefly by reducing glucose production in the liver and improving insulin sensitivity, while glimepiride is a sulfonylurea that stimulates the pancreas to release more insulin. Combining them in a single tablet is intended to improve blood-sugar control and simplify treatment for people whose diabetes is not adequately managed by one agent alone.
Sitagliptin is an oral antidiabetic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, often called a gliptin, used to improve blood-sugar control in adults with type 2 diabetes. It works by prolonging the action of the body's own incretin hormones, boosting insulin release and curbing glucagon after meals. Developed by Merck and approved in 2006 under the brand name Januvia, it is frequently combined with metformin.